ArticleDigestive diseases and sciences2025
Roles of Hypoxia and Mitochondrial Energy Metabolism Related Genes in Predicting the Prognosis of Liver Hepatocellular Carcinoma.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeHypoxia and mitochondrial dysfunctions are key contributors to the progression of liver hepatocellular carcinoma (LIHC). This study aimed to investigate the roles of hypoxia and mitochondrial energy metabolism-related differentially expressed genes (HMEMRDEGs) in the prognosis of LIHC.
methodsHMEMRDEGs were identified from the LIHC cohort from the Cancer Genome Atlas (TCGA) dataset by intersecting DEGs from TCGA-LIHC with hypoxia-related genes (HRGs) and mitochondrial energy metabolism-related genes (MEMRGs). The prognostic impact of HMEMRDEGs was determined, and enrichment analyses were performed on essential genes. A HMEMRDEGs-based risk score system was established using LASSO and multivariable Cox regression analyses. High- and low-risk patient groups were subjected to gene set variation, immune infiltration, and immunophenoscore analyses. A nomogram was established by combining the clinical features of patients with LIHC using a risk model.
resultsTwenty-eight HMEMRDEGs were identified. A prognostic model based on five key HMEMRDEGs revealed distinct biological characteristics between high- and low-risk LIHC groups. Functional enrichment analyses showed that these genes were involved in glucose metabolism and cancer-related signaling pathways, including AMPK and PI3K/Akt/mTOR. GSVA and immune infiltration analyses demonstrated that the high-risk group was enriched in oncogenic pathways and exhibited a more immunosuppressive microenvironment. Additionally, the high-risk group had significantly lower immunophenoscores, suggesting reduced responsiveness to immunotherapy.
conclusionsOur results demonstrate the profound impact of HMEMRDEGs on LIHC progression. We established a predictive risk model incorporating 5 key genes, which serves as a prognostic predictor in LIHC.
Indexed as
Identifiers
40593344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.